3/4
08:00 am
vir
Vir Biotechnology (VIR) had its price target raised by HC Wainwright from $15.00 to $20.00. They now have a "buy" rating on the stock.
Low
Report
Vir Biotechnology (VIR) had its price target raised by HC Wainwright from $15.00 to $20.00. They now have a "buy" rating on the stock.
2/28
06:33 am
vir
Vir Biotechnology Astellas Deal Puts VIR-5500 And Valuation In Focus [Yahoo! Finance]
Low
Report
Vir Biotechnology Astellas Deal Puts VIR-5500 And Valuation In Focus [Yahoo! Finance]
2/26
04:05 pm
vir
Vir Biotechnology to Participate in Upcoming Investor Conferences
Low
Report
Vir Biotechnology to Participate in Upcoming Investor Conferences
2/26
02:11 pm
vir
Vir Biotechnology (VIR) had its "outperform" rating reaffirmed by Leerink Partners.
Low
Report
Vir Biotechnology (VIR) had its "outperform" rating reaffirmed by Leerink Partners.
2/25
10:57 pm
vir
Vir Biotechnology Announces Pricing of Public Offering of Common Stock [Yahoo! Finance]
Medium
Report
Vir Biotechnology Announces Pricing of Public Offering of Common Stock [Yahoo! Finance]
2/25
10:31 pm
vir
Vir Biotechnology Announces Pricing of Public Offering of Common Stock
Medium
Report
Vir Biotechnology Announces Pricing of Public Offering of Common Stock
2/25
12:43 am
vir
A Look At Vir Biotechnology (VIR) Valuation After Astellas Collaboration On VIR-5500 And Early Phase 1 Update [Yahoo! Finance]
Medium
Report
A Look At Vir Biotechnology (VIR) Valuation After Astellas Collaboration On VIR-5500 And Early Phase 1 Update [Yahoo! Finance]
2/24
04:05 pm
vir
Vir Biotechnology Announces Proposed Public Offering of Common Stock
High
Report
Vir Biotechnology Announces Proposed Public Offering of Common Stock
2/24
03:08 pm
vir
Vir Biotechnology (VIR) had its "overweight" rating reaffirmed by Barclays PLC.
Low
Report
Vir Biotechnology (VIR) had its "overweight" rating reaffirmed by Barclays PLC.
2/24
12:43 pm
vir
Vir Biotechnology, Inc. Q4 2025 Earnings Call Summary [Yahoo! Finance]
Low
Report
Vir Biotechnology, Inc. Q4 2025 Earnings Call Summary [Yahoo! Finance]
2/24
10:17 am
vir
Biotech and Big Tech Drive the Morning Narrative
Low
Report
Biotech and Big Tech Drive the Morning Narrative
2/24
09:03 am
vir
Vir Biotechnology (NASDAQ:VIR) had its "outperform" rating reaffirmed by analysts at Evercore Inc.
Medium
Report
Vir Biotechnology (NASDAQ:VIR) had its "outperform" rating reaffirmed by analysts at Evercore Inc.
2/24
08:02 am
vir
Vir Biotechnology (NASDAQ:VIR) had its price target raised by analysts at Needham & Company LLC from $14.00 to $18.00. They now have a "buy" rating on the stock.
High
Report
Vir Biotechnology (NASDAQ:VIR) had its price target raised by analysts at Needham & Company LLC from $14.00 to $18.00. They now have a "buy" rating on the stock.
2/24
07:18 am
vir
Vir Biotechnology (NASDAQ:VIR) had its "overweight" rating reaffirmed by analysts at Morgan Stanley.
High
Report
Vir Biotechnology (NASDAQ:VIR) had its "overweight" rating reaffirmed by analysts at Morgan Stanley.
2/24
07:01 am
vir
Vir Biotechnology (NASDAQ:VIR) was upgraded by analysts at Raymond James Financial, Inc. from an "outperform" rating to a "strong-buy" rating.
High
Report
Vir Biotechnology (NASDAQ:VIR) was upgraded by analysts at Raymond James Financial, Inc. from an "outperform" rating to a "strong-buy" rating.
2/24
12:21 am
vir
Vir Biotechnology Q4 Earnings Call Highlights [Yahoo! Finance]
High
Report
Vir Biotechnology Q4 Earnings Call Highlights [Yahoo! Finance]
2/23
05:14 pm
vir
Vir Biotechnology Provides Corporate Update and Reports Fourth Quarter and Full Year 2025 Financial Results
High
Report
Vir Biotechnology Provides Corporate Update and Reports Fourth Quarter and Full Year 2025 Financial Results
2/23
05:02 pm
vir
Vir Biotechnology Reports Positive Updated Phase 1 Results for PSMA-targeting, PRO-XTEN® Dual-masked T-Cell Engager VIR-5500 in Patients with Metastatic Prostate Cancer
Low
Report
Vir Biotechnology Reports Positive Updated Phase 1 Results for PSMA-targeting, PRO-XTEN® Dual-masked T-Cell Engager VIR-5500 in Patients with Metastatic Prostate Cancer
2/23
05:00 pm
vir
Astellas and Vir Biotechnology Announce Global Strategic Collaboration to Advance PSMA-targeting PRO-XTEN® Dual-masked T-Cell Engager VIR-5500 for the Treatment of Prostate Cancer
High
Report
Astellas and Vir Biotechnology Announce Global Strategic Collaboration to Advance PSMA-targeting PRO-XTEN® Dual-masked T-Cell Engager VIR-5500 for the Treatment of Prostate Cancer
2/20
07:12 pm
vir
Vir Biotechnology Inc (VIR) Q4 2025 Earnings Report Preview: What To Expect [Yahoo! Finance]
Low
Report
Vir Biotechnology Inc (VIR) Q4 2025 Earnings Report Preview: What To Expect [Yahoo! Finance]
2/20
03:02 pm
vir
Catalyst Watch: Nvidia blockbuster, JPMorgan event, and reactions to the tariff reset [Seeking Alpha]
Neutral
Report
Catalyst Watch: Nvidia blockbuster, JPMorgan event, and reactions to the tariff reset [Seeking Alpha]
2/17
08:10 am
vir
Vir Biotechnology (NASDAQ:VIR) was given a new $26.00 price target on by analysts at Barclays PLC.
Low
Report
Vir Biotechnology (NASDAQ:VIR) was given a new $26.00 price target on by analysts at Barclays PLC.
2/9
04:46 pm
vir
Vir Biotechnology to Host Conference Call for Fourth Quarter and Full Year 2025 Financial Results [Yahoo! Finance]
Medium
Report
Vir Biotechnology to Host Conference Call for Fourth Quarter and Full Year 2025 Financial Results [Yahoo! Finance]
2/9
04:05 pm
vir
Vir Biotechnology to Host Conference Call for Fourth Quarter and Full Year 2025 Financial Results
Medium
Report
Vir Biotechnology to Host Conference Call for Fourth Quarter and Full Year 2025 Financial Results
2/9
08:04 am
vir
Vir Biotechnology (NASDAQ:VIR) had its "buy" rating reaffirmed by analysts at Needham & Company LLC. They now have a $14.00 price target on the stock.
Low
Report
Vir Biotechnology (NASDAQ:VIR) had its "buy" rating reaffirmed by analysts at Needham & Company LLC. They now have a $14.00 price target on the stock.